SSG
VRTX icon

Summit Securities Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Summit Securities Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-763
Closed -$346K – 1403
2025
Q4 		$346K Buy
763
+679
+808% +$293K 0.05% 245
2025
Q3 		$32.9K Buy
+84
New +$35.1K 0.01% 660
2025
Q2 		– Sell
-10
Closed -$4.85K – 1459
2025
Q1 		$4.85K Sell
10
-32
-76% -$14.9K ﹤0.01% 608
2024
Q4 		$16.9K Buy
+42
New +$19.5K ﹤0.01% 399
2024
Q3 		– Sell
-34
Closed -$16K – 891
2024
Q2 		$16K Buy
+34
New +$14.8K ﹤0.01% 402
2024
Q1 		– Sell
-21
Closed -$9K – 929
2023
Q4 		$9K Sell
21
-8
-28% -$2.96K ﹤0.01% 526
2023
Q3 		$10K Sell
29
-59
-67% -$20.6K ﹤0.01% 429
2023
Q2 		$31K Buy
+88
New +$29.6K ﹤0.01% 533
2022
Q4 		– Sell
-1,008
Closed -$292K – 1392
2022
Q3 		$292K Buy
+1,008
New +$290K 0.02% 351
2022
Q2 		– Sell
-1,151
Closed -$300K – 1244
2022
Q1 		$300K Buy
+1,151
New +$273K 0.03% 305
2013
Q3 		– Sell
-100
Closed -$8K – 560
2013
Q2 		$8K Buy
+100
New +$7.36K ﹤0.01% 345

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Summit Securities Group's VRTX Position: Q1 2026 in Review

Summit Securities Group sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 763 shares — an estimated $346K sold.

Summit Securities Group first reported a position in VRTX in Q2 2013 and held it in 11 quarters. The position peaked at $346K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Summit Securities Group reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Summit Securities Group sold 763 Vertex Pharmaceuticals shares in Q1 2026, an estimated $346K.
  • Summit Securities Group first reported a position in Vertex Pharmaceuticals in Q2 2013 and held it in 11 quarters.
  • Summit Securities Group's Vertex Pharmaceuticals position peaked at $346K in Q4 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Summit Securities Group's 13F filing for Q1 2026, filed 30 Apr 2026.